Jim Shannon

Jim Shannon

Democratic Unionist Party — Strangford

Speaking in the House of Commons on 17 November 2026

Debate

Medicines and Healthcare Products Regulatory Agency

Contribution

It is a pleasure to serve under your chairship, Sir John. I thank the right hon. Member for Tatton (Esther McVey) and the hon. Member for Blackley and Middleton South (Graham Stringer) for securing the debate. It is always good to see the Minister in his place; last night he did an Adjournment debate, and this morning he is doing a Westminster Hall debate, so he and I travel similar roads, although he is the man with all the responsibility. I want to speak about the performance of the MHRA in relation to a slightly different subject—the accessibility of medications—and it is important that I put it on the record. The regulatory agency does important work—I will make this case very clearly—in ensuring that our medical treatments meet the appropriate standards of safety, quality and effectiveness, and we must give it some credit. However, approved medicines cannot be effective if patients cannot access them in the first place. There are currently widespread shortages across the United Kingdom—that is a fact of life. The National Pharmacy Association, which represents about 6,000 independent community pharmacies, states that 96% of pharmacies feel that current shortages pose a serious risk to the safety of patients. I have that very issue of access to medicines in my constituency. I will give a personal example, and then a couple of examples of others whose health has been detrimentally affected by the shortage of medications. About six weeks ago, I was diagnosed with glaucoma, but the great thing is that people can take drops in their eyes to stop the condition getting any worse. However, access to those drops is difficult to achieve in parts of Northern Ireland, and they have to be ordered in advance and in excess to carry over. That is an example of where things go wrong. In recent months, there have been record shortages of commonly dispensed medicines such as painkillers and blood pressure and epilepsy medication. I have constituents who have difficulty accessing medicines, and there are serious shortage protocols in place for hormone replacement therapy treatments and Creon—a drug to help those with pancreatic cancer or cystic fibrosis digest food, just so they can have a normal quality of life. It is clear that these shortages are not discriminatory: they affect the mildly ill to the most seriously ill, and any one of us could be affected. The shortages have come alongside increased reports of pharmacy teams facing abuse or anger from patients whose prescribed medicine is unavailable. That is of course unacceptable on all occasions and under any circumstances, but it makes it clear that frontline pharmacists are also paying a price for medicine shortages and chronic underfunding. The Minister is always very responsive to our questions, and I know that he sets out to try to help us and that he has regular conversations with the relevant Minister back home, so what discussions has he had with them to address the acute shortages in Northern Ireland? This is a UK-wide issue, but the situation is particularly precarious in Northern Ireland due to its small market and additional logistical costs. There are concerns that, due to Brexit, Northern Ireland has become a lower-priority market for medicine wholesalers, and the worry is that that will have serious implications for patient safety. I understand that the drug companies have to make money—that is their purpose, and if they do not, they cannot be in profit or deliver the medicines—but consideration has to be given to us in Northern Ireland, where the problems are particularly difficult. Recently, a constituent came to me and made a very moving appeal for these shortages to be urgently addressed. This honourable, lovely, very happy lady has great disablement: she has multiple sclerosis, and has been on the drug Nabilone for 17 years to manage her pain. Just last month, she ran out of that medication and was forced to spend two weeks in bed due to a disruption in supply. That demonstrates the real human cost of medicine shortages: every pill missed is not just a missed dose; it is a lifeline lost. We in this House need to be aware of that.

More from Jim Shannon

Other recent Hansard contributions by the same speaker.

About Hansard

Hansard is the official verbatim record of proceedings in the UK Parliament. Every word spoken in the Commons and Lords is recorded and published — this page is a single contribution from that record.

For Jim Shannon's full parliamentary record including voting history, expenses and all other contributions, see the Jim Shannon report card.